- Home
- GKOS vs TXT Comparison
GKOS vs TXT Comparison
Compare GKOS & TXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- TXT
- Stock Information
- Founded
- GKOS 1998
- TXT 1923
- Country
- GKOS United States
- TXT United States
- Employees
- GKOS N/A
- TXT N/A
- Industry
- GKOS Medical/Dental Instruments
- TXT Aerospace
- Sector
- GKOS Health Care
- TXT Industrials
- Exchange
- GKOS Nasdaq
- TXT Nasdaq
- Market Cap
- GKOS 5.1B
- TXT N/A
- IPO Year
- GKOS 2015
- TXT N/A
- Fundamental
- Price
- GKOS $96.63
- TXT $68.42
- Analyst Decision
- GKOS Strong Buy
- TXT Hold
- Analyst Count
- GKOS 13
- TXT 9
- Target Price
- GKOS $155.00
- TXT $89.11
- AVG Volume (30 Days)
- GKOS 1.0M
- TXT 1.7M
- Earning Date
- GKOS 04-30-2025
- TXT 04-24-2025
- Dividend Yield
- GKOS N/A
- TXT 0.12%
- EPS Growth
- GKOS N/A
- TXT N/A
- EPS
- GKOS N/A
- TXT 4.44
- Revenue
- GKOS $383,481,000.00
- TXT $13,873,000,000.00
- Revenue This Year
- GKOS $27.84
- TXT $7.85
- Revenue Next Year
- GKOS $27.99
- TXT $4.52
- P/E Ratio
- GKOS N/A
- TXT $15.44
- Revenue Growth
- GKOS 21.85
- TXT 0.57
- 52 Week Low
- GKOS $77.91
- TXT $57.70
- 52 Week High
- GKOS $163.71
- TXT $94.57
- Technical
- Relative Strength Index (RSI)
- GKOS 50.06
- TXT 51.09
- Support Level
- GKOS $87.17
- TXT $64.05
- Resistance Level
- GKOS $98.86
- TXT $66.83
- Average True Range (ATR)
- GKOS 5.59
- TXT 2.84
- MACD
- GKOS 1.78
- TXT 0.56
- Stochastic Oscillator
- GKOS 88.89
- TXT 97.99
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.